Supporting Information

Blackmore et al. 10.1073/pnas.1620415114




Fig. S1. Transgenic 2D2 mice survive infection with influenza. Control C57BL/6J and transgenic 2D2 mice were inoculated with influenza. (A and B) The effects of inoculation with 1.0 HAU on C57BL/6J (open circles) and transgenic 2D2 (closed squares) survival (A) and weight loss (B). Fewer 2D2 mice met the criteria for euthanasia following 0.7 HAU inoculation (A), although these mice exhibited prolonged sickness as determined by weight loss (B). Results in A are combined from four independent experiments. For C57BL/6 mice, A are expressed as means A SE (A = 5–7 per group). *A Ps < 0.05.

Gating Strategy




Fig. S2. Gating strategy for comparing percentages of leukocytes isolated from the brain of 2D2 mice. The gating strategy used to determine viable and single cells obtained from the brains of saline- and influenza-inoculated 2D2 mice. This gating strategy was used to generate data shown in Fig. 1.




Fig. S3. IFN genes are up-regulated in the cerebellum and spinal cord at day 4 p.i. (A) Gene ontology analysis of the cerebellum at day 4 p.i. The numbers of genes associated with each GO term are shown in parentheses. (B and C) Top putative regulon controlling expression of up-regulated genes in the spinal cord (Left) and cerebellum (Right) as well as the top transcription factor-binding motif (C) as determined by iRegulon analysis. Analysis were performed on 20 kb flanking the transcriptional start site of each target gene. (D and E) Top five putative regulons, the percentage of target genes, and normalized enrichment scores identified from cerebellar and spinal cord up-regulated genes. (F and G) Interferome analysis conducted on up-regulated genes in the cerebellum (Left) and spinal cord (Right). For all up-regulated genes, fold change was >1.5 and FDR was <0.05.




Fig. S4. Bioinformatic analysis of up-regulated genes at day 8 p.i. (A) Significant gene ontology terms of up-regulated genes showing >1.4-fold change in expression and an FDR <0.05 in the cerebellum (*Left*) and spinal cord (*Right*). The numbers of genes associated with a GO term are shown in parentheses. The numbers of genes comprising the GO term immune system process that are distinct and shared between each tissue (*B*). (*C* and *D*) Gene regulatory network analysis showing the top five transcription factors and their putative targets for cerebellar (*C*) and spinal cord (*D*) genes. (*E*) Putative transcriptional regulators of shared genes (*Top*), their expression levels compared with control samples (*Bottom, Left*), and the top transcription factor-binding motifs (*Bottom, Right*). Scale bar for shared up-regulated genes is shown.




Fig. S5. Influenza inoculation increased T-cell surveillance of the brain. (A–E) Mice were inoculated with saline (n = 12) or influenza (n = 20). On days 2, 4, 8, and 16 p.i., CNS-IL were isolated and stained with antibodies specific for hematogenous cells (CD45 $^+$), T-cells (CD3 $^+$), and B-cells (CD19 $^+$). (A) Effect of infection on weights (Left) and total number of cells isolated from brain (Right). (B) Gating strategy for viable and single cells. (C and D) Representative flow cytometry plots, cell percentage, and numbers of CD45 $^+$ CD3 $^+$ T-cells (C) and CD45 $^+$ CD19 $^+$ B-cells (D) in saline-inoculated mice (D = 3) and influenza-inoculated mice (D = 5) at days 2, 4, 8, and 16 in the brain. Significance was determined by two-way ANOVA. Results are means D SE; **D < 0.01.




Fig. S6. The effect of infection on monocyte and neutrophil brain infiltration. (A–E) C57BL/6 mice were inoculated with saline or influenza (1.0 HAU), and brain-infiltrating lymphocytes were isolated by percoll gradient centrifugation at days 2, 4, and 8 p.i. (A) Gating strategy used to determine viable (Left) and single (Middle) cells. Antibodies specific for CD45 and CD11b were used to determine microglia (CD45^{int}CD11b⁺), lymphocytes (CD45⁺CD11b⁻), and myeloid cells (CD45^{hi}CD11b⁺) (Right). (Right). (Right) The total number of recovered cells (Left) and microglia (Right) are shown. (C and D) The effect of infection on the percentages and numbers of lymphocytes (C) and myeloid cells (D) is shown. Results are expressed as means \pm SE from two independent experiments (Right) and those represented in Fig. 5 (black). Individual mice are shown. Results are expressed as means \pm SE (Right) in the brain from experiments described above (gray) and those represented in Fig. 5 (black). Individual mice are shown. Results are expressed as means \pm SE (Right) and neutrophils (Right). Statistical analyses were done using two-way ANOVAs. Main effects are shown in Right. Results are from two independent experiments (Right) and are expressed as means \pm SE; Right0.0.5, **Right9 per group) and are expressed as means \pm SE; *Right9 per group) and are expressed as means \pm SE; *Right9 per group).




Fig. 57. Gating strategy for comparing percentages of leukocytes isolated from brain and blood. (*A* and *B*) The gating strategy used to determine the effect of infection on percentages of B-cells (CD45^{hi}CD19⁺), T-cells (CD45^{hi}CD3⁺), and monocyte/neutrophils (CD45^{hi}CD11b⁺) isolated from the brain (*A*) and peripheral blood (*B*) is shown.




Fig. S8. Infection increases the percentage of MHC class II-expressing B-cells in the CNS. (A–C) C57BL/6 mice were inoculated with sterile saline or influenza (1.0 HAU) i.n., and MHC class II expression on myeloid/microglia (CD11b⁺) and B-cells (CD19⁺) was examined by flow cytometry during the course of infection. (A and B) Gating strategy for identifying MHC class II-expressing cells in the CNS of naive mice. (C) The effect of infection on MHC class II mean fluorescent intensity of CD11b⁻CD19⁺ B-cells during the course of infection is shown. Results are expressed as means \pm SE. Individual mice are shown (n = 4–10 per group). Results at day 8 p.i. are from two cohorts of mice that are distinguishable by color. ***P < 0.001.

Table S1. Patient demographics for CSF samples in relapsingremitting multiple sclerosis patients in relapse or remission

Sex	Age (y)*	Disease status	Therapy
М	42	Relapse	IFN-β
M	29	Relapse	IFN-β
M	31	Relapse	NA
M	42	Relapse	NA
M	47	Relapse	NA
M	53	Relapse	NA
F	37	Relapse	NA
M	58	Relapse	NA
M	49	Relapse	NA
M	47	Relapse	NA
M	35	Remission	Copolymer-1
M	32	Remission	Copolymer-1
M	32	Remission	NA
M	39	Remission	NA
F	51	Remission	Chlorambucil
F	44	Remission	Chlorambucil
F	51	Remission	Chlorambucil
M	40	Remission	Chlorambucil
M	48	Remission	Chlorambucil
М	25	Remission	Chlorambucil

Information not available (NA).

^{*}Age did not differ between groups.